TREATING CHILDREN TO PREVENT EXACERBATIONS OF ASTHMA (TREXA)

治疗儿童预防哮喘恶化 (TREXA)

• 批准号: 8166624
• 负责人: HENGAMEH RAISSY
• 金额: $ 3.82万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166624
• 关键词: 5 year old; Adrenal Cortex Hormones; Albuterol; Asthma; Beclomethasone; Breathing; Budesonide; Child; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Guidelines; Institution; Patients; Pharmaceutical Preparations; Phase III Clinical Trials; Research; Research Personnel; Resources; Source; Symptoms; United States Food and Drug Administration; United States National Institutes of Health; base; fluticasone; prevent; standard of care

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This research is studying how to safely stop daily asthma medication, called inhaled corticosteroids and manage asthma exacerbations when they happen. Asthma guidelines recommend stopping the use of inhaled corticosteroids (such as fluticasone, beclomethasone, budesonide, and mometasone) when asthma has been controlled for 1-3 months. Although daily asthma symptoms may be controlled, some people may still have asthma exacerbations after stopping their daily inhaled corticosteroid medication. The standard of care is to use albuterol to control asthma exacerbations. However, in this study we would like to see if asthma exacerbations can be better managed if an inhaled cortocosteroid, called beclomethasone HFA is used, in addition to albuterol on an 'as needed' basis. This is a phase III trial meaning that the use of beclomethasone HFA in combination with albuterol for the management of asthma exacerbation is INVESTIGATIONAL. The Food and Drug Administration [FDA] has not approved the use of this combination for the management of asthma exacerbations. However, beclomethasone HFA has been approved to be used in the maintenace of asthma in patients 5 years of age and older. There are studies that have shown that similar combinations have managed asthma exacerbation better.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究正在研究如何安全地停止每天的哮喘药物，称为吸入性皮质类固醇，并在发生哮喘急性发作时进行管理。 哮喘指南建议，当哮喘得到1-3个月的控制时，应停止使用吸入性皮质类固醇（如氟替卡松、倍氯米松、布地奈德和莫米松）。 虽然日常哮喘症状可以得到控制，但有些人在停止每日吸入皮质类固醇药物后仍可能发生哮喘恶化。 标准治疗是使用沙丁胺醇控制哮喘恶化。 然而，在这项研究中，我们想看看如果在沙丁胺醇的基础上使用吸入性皮质类固醇，称为倍氯米松HFA，是否可以更好地控制哮喘急性发作。 这是一项III期试验，意味着使用倍氯米松HFA联合沙丁胺醇治疗哮喘急性发作是预防性的。 美国食品药品监督管理局（FDA）尚未批准使用该组合治疗哮喘急性发作。 然而，倍氯米松HFA已被批准用于5岁及以上哮喘患者的维持治疗。 有研究表明，类似的组合可以更好地控制哮喘急性发作。